(Q39658091)

13 September 2017

title

Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src (English)

1 reference

13 September 2017

Purvalanol A, a CDK inhibitor, effectively suppresses Src‐mediated transformation by inhibiting both CDKs and c‐Src (English)

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

9 July 2024

author name string

Tomoya Hikita

1

1 reference

13 September 2017

Chitose Oneyama

2

1 reference

13 September 2017

Masato Okada

3

1 reference

13 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20825494

9 July 2024

publication date

5 September 2010

1 reference

full work available at URL

13 September 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2443.2010.01439.x

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20825494

http://intl.genestocellsonline.org/cgi/content/abstract/15/10/1051

9 July 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20825494

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2443.2010.01439.x

9 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2443.2010.01439.x

9 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

9 July 2024

1 reference

13 September 2017

volume

15

1 reference

13 September 2017

issue

10

1 reference

13 September 2017

page(s)

1051-1062

1 reference

Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation

13 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro

9 July 2024

2

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

p27(kip1) functional regulation in human cancer: a potential target for therapeutic designs.

9 July 2024

3

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Crystal structures of active SRC kinase domain complexes

9 July 2024

4

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Regulation, substrates and functions of src

9 July 2024

5

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis

9 July 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2

9 July 2024

7

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds

9 July 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

9 July 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Receptor tyrosine kinases: the main targets for new anticancer therapy

9 July 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

A microplate assay for quantitation of anchorage-independent growth of transformed cells

9 July 2024

11

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Inhibitors of anchorage-independent growth affect the growth of transformed cells on poly(2-hydroxyethyl methacrylate)-coated surfaces

9 July 2024

12

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

9 July 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases

9 July 2024

15

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

The role of tyrosine phosphorylation in cell growth and disease

9 July 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation

9 July 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Degradation of p53 only is not sufficient for the growth stimulatory effect of human papillomavirus 16 E6 oncoprotein in human embryonic fibroblasts.

9 July 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

c-Src and cooperating partners in human cancer

9 July 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Cell transformation by the viral src oncogene

9 July 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases

9 July 2024

21

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Src kinases as therapeutic targets for cancer

9 July 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma

9 July 2024

23

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src

9 July 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Constitutive activation of Src family kinases in mouse embryos that lack Csk.

9 July 2024

25

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src

9 July 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Functional dissection of transformation by c-Src and v-Src.

9 July 2024

27

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy

9 July 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Csk defines the ability of integrin-mediated cell adhesion and migration in human colon cancer cells: implication for a potential role in cancer metastasis

9 July 2024

29

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer

9 July 2024

30

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Specific and redundant roles of Src and Fyn in organizing the cytoskeleton.

9 July 2024

31

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation

9 July 2024

32

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

9 July 2024

A renaissance for SRC

33

1 reference

https://api.crossref.org/works/10.1111/J.1365-2443.2010.01439.X

9 July 2024

Identifiers

1 reference

13 September 2017

1 reference